BioPharma Credit (LSE:BPCR) 6-Month Price Index: 1.03 (As of Sep. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:BPCR BioPharma Credit PLC LSE:BPCR
48 GF Score
Price $0.96
GF Value $0.96
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BioPharma Credit 6-Month Price Index?

BioPharma Credit LSE:BPCR -0.62% 48 6-Month Price Index is 1.03 as of Sep. 06, 2026. GuruFocus rates LSE:BPCR with a GF Score™ of 48/100 and a GF Value™ of $0.96 (Fairly Valued). The stock has 2 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-09-06), BioPharma Credit's 6-Month Price Index is 1.03.

BioPharma Credit  (LSE:BPCR) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

BioPharma Credit 6-Month Price Index Related Terms

LSE:BPCR vs BLK, BX, KKR: 6-Month Price Index Comparison

For the Asset Management subindustry, BioPharma Credit's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LSE:BPCR
48GF Score
BioPharma Credit PLC LSE:BPCR
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioPharma Credit  (LSE:BPCR) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 1.03 mean?
BioPharma Credit (LSE:BPCR) has a 6-Month Price Index of 1.03 as of Sep. 06, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on BioPharma Credit and its competitors.
Is BioPharma Credit's 6-Month Price Index too high?
BioPharma Credit's current 6-Month Price Index is 1.03. Overall, BioPharma Credit has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's 6-Month Price Index compare to BLK and BX?
BioPharma Credit's 6-Month Price Index of 1.03 can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for an Asset Management company?
A good 6-Month Price Index depends on the Asset Management industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on BioPharma Credit and its competitors. BioPharma Credit's current 6-Month Price Index is 1.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.96, compared to a current price of $0.96 — trading right at its estimated fair value. The current 6-Month Price Index is 1.03. BioPharma Credit's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current 6-Month Price Index is 1.03 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?

Based on GuruFocus' analysis, BioPharma Credit stock appears to be undervalued. The current stock price of $0.96 is trading 0% below its estimated GF Value™ of $0.96. GuruFocus considers BioPharma Credit to be Fairly Valued.

Key valuation signals for LSE:BPCR:

  • 6-Month Price Index: 1.03
  • GF Value™: $0.96 vs. price of $0.96 (0% below fair value)
  • GF Score™: 48/100 with 2 warning signs

No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioPharma Credit Business Description

Address c/o MUFG Corporate Governance Limited, 51 Lime Street, 19th Floor, London, GBR, EC3M 7DQ
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
48GF Score

Get the complete analysis for LSE:BPCR

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.96
Price
$0.96
GF Value